Predicting Outcomes in Colorectal Cancer Treatment
Author Information
Author(s): Freyer G, Rougier P, Bugat R, Droz J-P, Marty M, Bleiberg H, Mignard D, Awad L, Herait P, Culine S, Trillet-Lenoir V
Primary Institution: Medical Oncology Unit and EA 643, Centre Hospitalier Lyon-Sud, Lyon, France
Hypothesis
What are the significant predictive parameters for tumour response, progression-free survival, and toxicity in metastatic colorectal cancer patients treated with irinotecan after 5-FU failure?
Conclusion
Normal baseline haemoglobin levels and fewer organs involved are key factors that can help predict treatment outcomes in colorectal cancer patients.
Supporting Evidence
- Normal baseline haemoglobin level is a significant predictive factor for tumour growth control.
- WHO Performance Status and liver involvement are significant for progression-free survival.
- The study included 455 patients across four trials.
Takeaway
Doctors can use certain health indicators to guess how well a patient with colorectal cancer will respond to treatment and if they might have side effects.
Methodology
Data from four phase II trials were pooled for statistical analysis to identify predictive factors.
Limitations
The results need to be confirmed in future trials.
Participant Demographics
Patients with 5-FU resistant metastatic colorectal carcinoma.
Statistical Information
P-Value
P≤ 0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website